We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Omeros (OMER) Hits New 52-Week High on Positive FDA Decision
Read MoreHide Full Article
Omeros Corporation (OMER - Free Report) shares hit a new 52-week high of $22.80 on Thursday before eventually closing at $22.15.
Shares of the company rose almost 30% since the announcement that the FDA has granted breakthrough therapy designation to its lead pipeline candidate OMS721, which is being evaluated for the treatment of Immunoglobulin A nephropathy (IgAN). IgAN is a disease, which affects the ability of the kidneys to filter wastes from the blood. In fact, shares of the company hit fresh highs for three consecutive days since the announcement of the news.
In-fact, Omeros’ year-to-date share price movement shows that the stock has massively outperformed the Zacks classified Medical - Products industry, having surged 123.3% during this period, while the industry gained 19.5%.
We note that the breakthrough therapy designation is granted by the FDA to expedite the development and review of drugs that are intended to treat serious diseases so that patients can access the drug as soon as possible.
We are encouraged by the FDA’s decision. Per the press release, there are an estimated 120,000 to 180,000 patients with IgAN in the U.S., among which 40% develop end-stage renal disease, a life-threatening condition.
Moreover, there is no approved drug for the treatment of IgAN and OMS721 is the only candidate in this indication that has been granted this designation.
The breakthrough therapy designation was granted based on data from a phase II study evaluating OMS721 for the treatment of IgAN and other kidney diseases. The data showed an average reduction of 77% in urine albumin-to-creatinine ratios as well as a 73% mean reduction in 24-hour urine protein levels after 12 weeks of treatment. Also, unprecedented improvement was seen in proteinuria, an important marker for disease progression in patients with IgAN in the same period.
Omeros is also developing the candidate in other indications and reported positive results from the studies in its first-quarter earnings release. The candidate has also been granted orphan drug status for the prevention of complement-mediated TMAs and fast track designation for the treatment of patients with atypical hemolytic uremic syndrome (aHUS).
Meanwhile, the company’s only marketed drug, Omidria is approved for cataract surgery and lens replacement procedures to maintain pupil size in both the U.S. and Europe. The drug recorded sales of $12.3 million, up almost 69% year over year, showing strong growth.
VIVUS’ loss per share estimates have narrowed from 50 cents to 39 cents for 2017 in the last 60 days. The company delivered positive earnings surprises in the four trailing quarters, with an average beat of 233.69%.
MEI Pharma’s estimates have moved up from loss per share of 1 cent to earnings per share of 1 cent for 2017 in the last 60 days. The company delivered positive earnings surprises in three of the four trailing quarters, with an average beat of 66.56%.
Geron’s loss per share estimates have narrowed from 10 cents to 9 cents for 2017 over the last 60 days. The company delivered positive earnings surprises in each of the four trailing quarters, with an average beat of 27.98%.
3 Top Picks to Ride the Hottest Tech Trend
Zacks just released a Special Report to guide you through a space that has already begun to transform our entire economy...
Last year, it was generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early. Download Report with 3 Top Tech Stocks >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Omeros (OMER) Hits New 52-Week High on Positive FDA Decision
Omeros Corporation (OMER - Free Report) shares hit a new 52-week high of $22.80 on Thursday before eventually closing at $22.15.
Shares of the company rose almost 30% since the announcement that the FDA has granted breakthrough therapy designation to its lead pipeline candidate OMS721, which is being evaluated for the treatment of Immunoglobulin A nephropathy (IgAN). IgAN is a disease, which affects the ability of the kidneys to filter wastes from the blood. In fact, shares of the company hit fresh highs for three consecutive days since the announcement of the news.
In-fact, Omeros’ year-to-date share price movement shows that the stock has massively outperformed the Zacks classified Medical - Products industry, having surged 123.3% during this period, while the industry gained 19.5%.
We note that the breakthrough therapy designation is granted by the FDA to expedite the development and review of drugs that are intended to treat serious diseases so that patients can access the drug as soon as possible.
We are encouraged by the FDA’s decision. Per the press release, there are an estimated 120,000 to 180,000 patients with IgAN in the U.S., among which 40% develop end-stage renal disease, a life-threatening condition.
Moreover, there is no approved drug for the treatment of IgAN and OMS721 is the only candidate in this indication that has been granted this designation.
The breakthrough therapy designation was granted based on data from a phase II study evaluating OMS721 for the treatment of IgAN and other kidney diseases. The data showed an average reduction of 77% in urine albumin-to-creatinine ratios as well as a 73% mean reduction in 24-hour urine protein levels after 12 weeks of treatment. Also, unprecedented improvement was seen in proteinuria, an important marker for disease progression in patients with IgAN in the same period.
Omeros is also developing the candidate in other indications and reported positive results from the studies in its first-quarter earnings release. The candidate has also been granted orphan drug status for the prevention of complement-mediated TMAs and fast track designation for the treatment of patients with atypical hemolytic uremic syndrome (aHUS).
Meanwhile, the company’s only marketed drug, Omidria is approved for cataract surgery and lens replacement procedures to maintain pupil size in both the U.S. and Europe. The drug recorded sales of $12.3 million, up almost 69% year over year, showing strong growth.
Omeros Corporation Price and Consensus
Omeros Corporation Price and Consensus | Omeros Corporation Quote
Zacks Rank & Stocks to Consider
Omeros currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks in the health care sector include VIVUS, Inc. , MEI Pharma, Inc. (MEIP - Free Report) and Geron Corporation (GERN - Free Report) . VIVUS and Mei Pharma sport a Zacks Rank #1 (Strong Buy) while Geron carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
VIVUS’ loss per share estimates have narrowed from 50 cents to 39 cents for 2017 in the last 60 days. The company delivered positive earnings surprises in the four trailing quarters, with an average beat of 233.69%.
MEI Pharma’s estimates have moved up from loss per share of 1 cent to earnings per share of 1 cent for 2017 in the last 60 days. The company delivered positive earnings surprises in three of the four trailing quarters, with an average beat of 66.56%.
Geron’s loss per share estimates have narrowed from 10 cents to 9 cents for 2017 over the last 60 days. The company delivered positive earnings surprises in each of the four trailing quarters, with an average beat of 27.98%.
3 Top Picks to Ride the Hottest Tech Trend
Zacks just released a Special Report to guide you through a space that has already begun to transform our entire economy...
Last year, it was generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early. Download Report with 3 Top Tech Stocks >>